Preventing Acute Hepatitis and Liver Inflammation

Vaqta is applied in addressing conditions associated with the Hepatitis A virus (HAV), which is linked to acute liver inflammation. The primary therapeutic benefit is in reducing the risk of developing a serious symptomatic illness, helping patients cope more steadily with the potential for manifestations like jaundice, severe malaise and fatigue (symptoms related to systemic imbalance), fever, and pronounced gastrointestinal disruption (symptoms that interfere with daily functioning). This measure is used for individuals 12 months and older, including international travelers to high-risk areas, those with chronic liver disease, and individuals in high-risk occupational settings. For these groups, Vaqta contributes to reducing the risk of developing severe acute illness, assisting with maintaining stability when symptoms interfere with routine activities.

---

Mitigating Risk for Vulnerable Patient Groups

The vaccine is considered relevant for supportive protection for specific populations who face either heightened exposure or increased risk of severe outcomes. It is commonly used across conditions presenting with acute episodes, helping to manage the potential for critical manifestations.

---

Quick Fact: Relief for Systemic Viral Symptoms The goal of immunization is to help manage the risk of developing symptoms related to systemic imbalance and acute hepatic distress—a therapeutic approach that contributes to maintaining functional stability by significantly reducing the likelihood of infection-related discomfort.

VAQTA is officially indicated for the prevention of disease caused by the Hepatitis A virus in persons 12 months of age and older. Regulatory documents specify both populations eligible for use and those who must not use the vaccine, or for whom use is conditional.

Contraindications and Non-Eligibility

Category	Regulatory Status
Absolute Contraindication	History of immediate and/or severe allergic reactions (e.g., anaphylaxis) to a previous dose of any Hepatitis A vaccine or to any component of VAQTA, including neomycin.
Minimum Age Exclusion	Infants below 12 months of age are excluded, as safety and effectiveness have not been established.

Conditional Use and Restrictions

Official labeling identifies specific groups for whom use is conditional or may result in an altered response:

• Immunological Status: Individuals who are immunocompromised (e.g., due to malignancy or immunosuppressive therapy) may have a diminished immune response and may not be protected.
• Acute Illness: Vaccination should generally be deferred in persons with moderate or severe acute illness, with or without fever.
• Pregnancy and Lactation: Use during pregnancy or breastfeeding is not recommended unless the clear need and potential benefits outweigh potential risks, as adequate and controlled studies on safety are lacking.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Vaqta primarily by assessing its effectiveness when administered with other substances, rather than through systemic metabolic mechanisms.

Category	Official Regulatory Information
Interacting Substances	Immunosuppressive therapies (e.g., high-dose corticosteroids, cytotoxic drugs, alkylating agents, antimetabolites) and Immune Globulin (Human).
Mechanistic Basis	Pharmacodynamic interaction that results in a diminished immune response to the vaccine. No documented interactions with the CYP enzyme system or transporter proteins are listed.

The most significant documented interaction involves substances that suppress the immune system. Co-administration with immunosuppressive therapies may lead to a diminished immune response, officially reducing the expected level of protective immunity. This is also a population-specific consideration, as immunocompromised persons or those with chronic liver disease may exhibit a lower antibody response.

Regulatory labeling permits the concomitant administration of Vaqta with Immune Globulin and certain other licensed vaccines, including those for Yellow Fever, Measles, Mumps, Rubella, and Varicella. The official restriction is a mandatory procedural constraint: Vaqta must not be mixed with any other vaccine in the same syringe or vial, and all co-administered injectables must be given at separate injection sites.

Vaqta is an inactivated, whole-virus vaccine containing purified Hepatitis A virus (HAV) antigen. The viral antigen is adsorbed onto an amorphous aluminum hydroxyphosphate sulfate adjuvant, which serves as a molecular and cellular signal to the innate immune system. The administration of the vaccine, typically via the intramuscular route into the deltoid muscle, facilitates the localized presentation of the HAV antigen.

Following administration, the HAV antigen is processed by antigen-presenting cells (APCs) in the local tissue and draining lymph nodes. The adjuvant enhances the uptake of the antigen and promotes the release of inflammatory mediators, leading to the activation and proliferation of both B-lymphocytes and T-lymphocytes.

Specifically, B-cells are stimulated to differentiate into plasma cells and memory B-cells. The plasma cells function as molecular factories, initiating the downstream cascade of anti-HAV antibody production, including the IgG and IgM classes, which target the viral protein. Concurrently, memory T-cells and memory B-cells are generated, constituting an adaptive immune system response. This system-level physiological modulation establishes an immunologic memory against the HAV protein.

How to Use Vaqta: Administration Guidelines

Vaqta is a sterile suspension for injection that is administered according to a two-dose schedule. The vaccine is supplied in two forms: a 0.5 mL dose for children and adolescents and a 1.0 mL dose for adults, with each dose volume corresponding to a different unit strength of the inactivated Hepatitis A virus antigen.

---

Administration Scope and Dosing

The route of administration is by intramuscular (IM) injection. For adults and adolescents over 2 years, the preferred injection site is the deltoid muscle. Subcutaneous administration may be considered for individuals with a bleeding disorder to reduce the risk of hemorrhage. The vaccine is not to be administered intravascularly.

Age Group	Dose Volume & Strength	Administration Schedule
Children/Adolescents (12 months–18 years)	0.5 mL (approx. 25 U)	Primary dose, followed by booster 6 to 18 months later
Adults (19 years and older)	1.0 mL (approx. 50 U)	Primary dose, followed by booster 6 to 18 months later

The primary dose is administered at least two weeks before expected exposure to the Hepatitis A virus. The 6 to 18 month interval for the second, or booster dose, completes the regimen.

---

Preparation and Procedural Rules

Before administration, the vial or prefilled syringe must be shaken well to achieve a slightly opaque, white, homogenous suspension. The product must be visually inspected, and if it appears discolored or contains extraneous particulate matter, it should be discarded. When Vaqta is administered alongside other vaccines or immune globulin, separate syringes and different injection sites are used, as the vaccine is not mixed with any other product in the same syringe.

Research Evidence / Overview of Studies for Vaqta

Evidence for Use in Preventing Hepatitis A Disease

Research exploring the use of Vaqta for the prevention of Hepatitis A disease has primarily involved randomized controlled trials (RCTs) and open-label studies. These studies were designed to evaluate the vaccine's interaction with the immune system, focusing on outcomes like seroconversion. Seroconversion is a measured outcome that is used to measure the establishment of a specific level of anti-Hepatitis A virus antibodies in the blood.

Studies monitored antibody levels at various time points after the initial and booster doses. Studies describe patterns where a large proportion of participants reached the measured seroconversion levels after completing the full vaccination series. Research examined measurements of antibody concentrations (Geometric Mean Titers, or GMTs), and findings suggest some variation between different age groups and study cohorts. These trials examined the vaccine in comparison to a placebo or against other Hepatitis A vaccines, with findings contributing to the broader evidence landscape.

Durability and Long-Term Follow-up Studies

Studies have been conducted to observe the long-term persistence of the immune response to Vaqta. These long-term investigations, which follow participants for years after the vaccination series is complete, help show what has been observed so far regarding how long the measured antibody levels may last.

Research has explored the patterns of anti-Hepatitis A virus antibodies observed in adults for at least six years following the full vaccination regimen. In some study cohorts, the measured immune response was observed for longer periods, with evidence describing the persistence of these antibody levels over many years. However, long-term effects are not fully established beyond the maximum current follow-up periods. There is limited information for long-term outcomes regarding antibody levels beyond the current study follow-up times, and research is ongoing to monitor these patterns.

Evidence in Different Age Groups and Specific Populations

Vaqta was studied for its immune response across various age ranges, including children (from 12 months of age), adolescents, and older adults. Research has explored the observed patterns of seroconversion in both pediatric and adult populations. Research was conducted in certain specific populations, such as individuals with chronic liver disease, to contribute to the understanding of this population. Data for certain groups, such as immunocompromised individuals or pregnant women, remain insufficient.

What Research Remains Unclear or Undocumented

Research provides context but not individual predictions, and there are several areas where data are still emerging or remain limited. Specifically, long-term effects on antibody levels beyond the current follow-up windows are not well characterized. Comparative evidence is lacking for certain combinations of Vaqta with other vaccines. The total duration of the measured immune response in healthy study participants is not fully established at present, and research is ongoing to better understand this timeline.

Common questions about Vaqta (FAQ)

Q: What is Vaqta and how is it used?

A: Vaqta is a vaccine indicated for the prevention of disease caused by the hepatitis A virus (HAV) in individuals 12 months of age and older. It is administered as an injection, typically into a muscle.

Q: How does Vaqta work to help prevent hepatitis A?

A: Vaqta contains an inactivated (non-living) form of the hepatitis A virus protein. When administered, the vaccine is intended to stimulate the body's immune system to produce disease-fighting substances, known as antibodies, against the hepatitis A virus. This process is expected to provide protection against the infection.

Q: Who is generally recommended to receive the Vaqta vaccine?

A: Vaqta is approved for use in persons 12 months of age and older. Groups who may be recommended to receive the vaccine include:

• All children starting at 1 year of age.
• Individuals who travel to or work in countries where hepatitis A is common.
• People who may be at an increased risk for infection.
• Anyone who seeks protection against hepatitis A.

Q: What are the common side effects reported with Vaqta?

A: Common reactions reported across clinical trials have typically been mild and short-lived. These may include:

• At the injection site: Pain, tenderness, soreness, redness, or warmth.
• Systemic reactions: Headache, fever (more than 99.5 F), a general feeling of discomfort or illness, or unusual tiredness.

Q: Can Vaqta be given with other vaccines?

A: Vaqta has been studied for simultaneous administration with certain other vaccines, such as typhoid Vi polysaccharide and yellow fever vaccines in adults. In these specific studies, the safety and immune response observed were similar when the vaccines were given together compared to when they were administered separately. If other vaccines are needed, they are typically given at separate injection sites.

Q: What should be considered regarding Vaqta and pregnancy or breastfeeding?

A: Limited data are available regarding the use of Vaqta in pregnant women. Post-approval data do not currently suggest an increased risk of miscarriage or major birth defects in women who received the vaccine during pregnancy. It is not known if the components of Vaqta are excreted in human milk. A healthcare provider is the appropriate person to discuss the potential benefits and any possible risks related to vaccination during pregnancy or while breastfeeding.

Q: Are there limitations to how effective Vaqta may be?

A: Like all vaccines, Vaqta may not result in a protective immune response in all recipients. Important limitations include:

• The vaccine may not prevent hepatitis A infection in individuals who already have an unrecognized infection at the time of vaccination, due to the long incubation period of the virus (approximately 20 to 50 days).
• Individuals with a weakened immune system, including those on immunosuppressive therapy, may have a diminished response to the vaccine and may not be protected against the virus.

Storage and Disposal Requirements for Vaqta

Storage Conditions

Vaqta (Hepatitis A Vaccine, Inactivated) must be stored in a refrigerator at temperatures strictly between 2 C and 8 C (36 F and 46 F) to maintain its potency. The product must be protected from light and stored in its original container. It is mandatory not to freeze Vaqta, as freezing permanently destroys the vaccine's effectiveness.

Handling and Safety

Prior to use, the suspension should be visually inspected; if it appears discolored or contains extraneous particulate matter, it must be discarded. Keep the vaccine out of the sight and reach of children.

Disposal Instructions

Any unused medicinal product or waste material, including used syringes and vials, must be disposed of in accordance with local requirements for pharmaceutical waste. Do not dispose of the vaccine in household trash or via wastewater.